In Vivo Weight-Loss Efficacy of GLP-1R, GIPR, and GCGR Agents in DIO and Humanized Rodent Models

GLP-1R, GIPR, and GCGR are key therapeutic targets in next-generation anti-obesity drug development, supported by clinical advances with dual GLP-1/GIP agonists and triple GLP-1/GIP/GCGR agonists such as retatrutide, which demonstrated substantial weight loss in Phase III clinical trials in 2026. However, limited translatability between conventional rodent preclinical models and human clinical responses remains a major challenge in metabolic drug development. Robust in vivo pharmacology studies using diet-induced obesity (DIO) models and GLP-1R, GIPR, and GCGR humanized rodent models are critical for characterizing metabolic drug candidates, addressing species-specific receptor differences, and evaluating translational potential early in the development pipeline.

In this webinar, our expert will share in vivo pharmacology data from DIO mice, rat models, and humanized models spanning single, dual, and triple GLP‑1R, GIPR, and GCGR targets to support metabolic drug candidate profiling. Attendees will gain practical references for model selection and in vivo benchmarking to inform candidate screening and translational research in obesity therapeutics.

Topics for this webinar include:

• Humanized Rodent Models and Mechanistic Overview of GLP-1R, GIPR, and GCGR Modulators
  

• Preclinical Case Studies: Weight-Loss Efficacy Assessment of GLP-1R Agonists, GIPR Agonists/Antagonists, and GCGR Agonists

• Standardized In Vivo Benchmark Datasets and Customized Model Selection Strategies for Different Compound Development Scenarios

Date: Tuesday, Aug 25, 2026

Time: 8:00 AM PDT | 10:00 AM CDT | 11:00 AM EDT | 5:00 PM CEST

Speaker: Dr. Marina Gao